Employers Cutting GLP-1 Coverage as Costs Rise
A survey indicates that roughly 14% of U.S. employers have either stopped or intend to stop covering GLP-1 medications by 2027. The decision is driven by escalating health care expenses.
A new survey reveals a notable shift in employer health benefits. Approximately one in seven U.S. employers have already discontinued or plan to discontinue coverage for GLP-1 drugs by 2027. The primary driver cited is the mounting financial burden these medications place on health plans.
These drugs, used for diabetes and weight management, carry significant price tags. As their popularity has grown, so have the costs absorbed by employers who sponsor health insurance. The survey suggests this trend may accelerate as more companies weigh the long-term value of such coverage against immediate budget pressures.
This development could reshape access to popular treatments for millions of Americans who rely on employer-sponsored insurance. Patients currently using GLP-1 medications may face sudden out-of-pocket costs or forced treatment changes. Employers, meanwhile, must balance workforce health needs against rising premiums. If more companies follow this path, it could widen disparities in healthcare access, particularly for those with lower incomes who cannot afford these drugs without insurance support.